EXAS

Exact Sciences Corp

Healthcare


Presented:12/18/2019
Price:$90.63
Cap:$11.77B
Current Price:$69.95
Cap:$12.92B

Presented

Date12/18/2019
Price$90.63
Market Cap$11.77B
Ent Value$11.39B
P/E RatioN/A
Book Value$5.76
Div Yield0%
Shares O/S129.83M
Ave Daily Vol2,232,758
Short Int9.95%

Current

Price$69.95
Market Cap$12.92B
EXACT Sciences Corp. is a molecular diagnostics company, which focuses on the early detection and prevention of colorectal cancer. It developed Cologuard, a screening test for the early detection of colorectal cancer and pre-cancer. The company was founded on February 10, 1995 and is headquartered in Madison, WI.

Publicly traded companies mentioned herein: Epigenomics AG (ECX GR), Exact Sciences Corporation (EXAS), Laboratory Corporation (LH)

Highlights

The presenter is short shares of Exact Sciences Corporation (EXAS), due to competition in the colon cancer screening space. Epigenomics, a company based in Germany, has received FDA approval for a blood test that is able to detect colon cancer with 70% sensitivity. He believes that if the blood test receives Medicare reimbursement in late 2020, that EXAS’s stock price will decline significantly. EXAS currently trades at 20x 2022 earnings and ~$96.00/share.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Request access to DeMatteo Research for full access

Request Access

Already have an account?

Idea Discussion

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Idea Discussions display submitted commentary from our investor community.

To read and participate in the discussion with the presenter and investor base, request access to DeMatteo

Request Access

Already have an account?

An error occurred loading this content. Try again later or contact us.